DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 74 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Stocks in news: Reliance Industries, Bank of Baroda, Power Grid, NATCO Pharma and JSW Infra

Economic Times 6d ago·24 Aug 2026, 12:30 am

Jubilant Pharmova announced that its US subsidiary received observations from the US Food and Drug Administration (US FDA) during a recent inspection. The company stated that these observations relate to certain manufacturing practices and are not related to the quality of the drug products. This is a standard part of the regulatory process and does not indicate a product recall or a halt in production.

For investors, this news may trigger short-term volatility as the market reacts to regulatory updates. While observations can sometimes lead to future enforcement actions if not addressed, they are often resolved through dialogue with the regulator. The company has a track record of working closely with US authorities to ensure compliance.

Investors should monitor the company's subsequent communications and any follow-up actions taken by the US FDA. It is also important to look at the broader context of the company's operations and its ability to maintain compliance across its global facilities.